We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
Cap. Flow
-$244M
Cap. Flow %
-5.15%
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19
Avg Time Held Equity + Options
7.6 quarters
Top 10 Avg Time Held Equity + Options
6.2 quarters
Top 20 Avg Time Held Equity + Options
5.8 quarters
Avg Time Held Equity only
8 quarters
Top 10 Avg Time Held Equity only
6.2 quarters
Top 20 Avg Time Held Equity only
5.8 quarters

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$95.5M
2
VKTX icon
Viking Therapeutics
VKTX
+$57.4M
3
ARGX icon
argenx
ARGX
+$52.2M
4
ADGM icon
Adagio Medical Holdings
ADGM
+$46.7M
5
ORKA icon
Oruka Therapeutics
ORKA
+$43M

Top Sells

Rank Stock Value
1
CERE icon
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$441M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$60M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$38.8M
5
SWTX icon
SpringWorks Therapeutics
SWTX
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
2 Miscellaneous 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EWTX icon
26
Edgewise Therapeutics
EWTX
$3.94B
$62.2M 1.32%
2,330,294
+473,877
+26% +$9.43M
2023 Q4
3 quarters
PTGX icon
27
Protagonist Therapeutics
PTGX
$8.96B
$61.9M 1.31%
1,374,563
+105,828
+8% +$4.28M
2023 Q1
6 quarters
MGTX icon
28
MeiraGTx Holdings
MGTX
$955M
$52.4M 1.11%
12,581,103
+1,250,000
+11% +$5.4M
2018 Q2
25 quarters
ALDX icon
29
Aldeyra Therapeutics
ALDX
$54.3M
$50M 1.06%
9,275,851
– –
2015 Q1
38 quarters
AKRO icon
30
DELISTED
Akero Therapeutics
AKRO
$49.2M 1.04%
1,714,806
+214,909
+14% +$5.6M
2022 Q3
8 quarters
SLDB icon
31
Solid Biosciences
SLDB
$624M
$48.1M 1.02%
6,906,646
– –
2020 Q2
17 quarters
TARS icon
32
Tarsus Pharmaceuticals
TARS
$3.31B
$42.6M 0.9%
1,296,416
– –
2020 Q4
15 quarters
XBI icon
33
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$39.5M 0.84%
+400,000
New +$39.3M
2024 Q3
0 quarters
ACRV icon
34
Acrivon Therapeutics
ACRV
$75M
$37.5M 0.79%
5,360,858
– –
2022 Q4
7 quarters
CRNX icon
35
DELISTED
Crinetics Pharmaceuticals
CRNX
$37M 0.78%
724,698
-751,505
-51% -$38.8M
2018 Q3
24 quarters
NAUT icon
36
Nautilus Biotechnolgy
NAUT
$261M
$35.9M 0.76%
12,594,211
– –
2021 Q2
13 quarters
CELC icon
37
Celcuity
CELC
$3.09B
$35.2M 0.75%
2,362,279
– –
2023 Q4
3 quarters
PODD icon
38
Insulet
PODD
$9.58B
$33.1M 0.7%
+142,269
New +$29.2M
2024 Q3
0 quarters
ORKA icon
39
Oruka Therapeutics
ORKA
$5.18B
$30.3M 0.64%
+1,235,187
New +$43M
2024 Q3
0 quarters
CTNM icon
40
Contineum Therapeutics
CTNM
$317M
$29M 0.61%
1,516,668
-50,000
-3% -$959K
2024 Q2
1 quarter
OCUL icon
41
Ocular Therapeutix
OCUL
$1.59B
$28.9M 0.61%
3,324,468
– –
2024 Q1
2 quarters
ISRG icon
42
Intuitive Surgical
ISRG
$149B
$28.6M 0.6%
58,119
-3,681
-6% -$1.71M
2023 Q4
3 quarters
NTRA icon
43
Natera
NTRA
$57B
$27.9M 0.59%
220,000
-310,000
-58% -$35.6M
2022 Q3
8 quarters
CGON icon
44
CG Oncology
CGON
$5.53B
$27.7M 0.59%
733,695
– –
2024 Q1
2 quarters
ZYME icon
45
Zymeworks
ZYME
$1.8B
$27.4M 0.58%
2,180,020
+512,309
+31% +$5.58M
2017 Q2
29 quarters
DYN icon
46
Dyne Therapeutics
DYN
$2.86B
$25.8M 0.55%
+718,144
New +$28.6M
2024 Q3
0 quarters
ADGM icon
47
Adagio Medical Holdings
ADGM
$3.41M
$25.3M 0.54%
+9,812,419
New +$46.7M
2024 Q3
0 quarters
ARVN icon
48
Arvinas
ARVN
$447M
$25.3M 0.54%
1,027,749
– –
2023 Q4
3 quarters
PRCT icon
49
Procept Biorobotics
PRCT
$1.09B
$25.3M 0.54%
315,659
+105,000
+50% +$7.46M
2024 Q1
2 quarters
NBIX icon
50
Neurocrine Biosciences
NBIX
$13.7B
$24.5M 0.52%
212,228
-437,681
-67% -$60M
2013 Q2
45 quarters
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $244M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.

  • Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
  • Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
  • Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
  • Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
  • Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.